The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Review of Anticancer Therapy

• Publication date

  2017-11-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14737140.2017.1398089PMID 29069959
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature

  2017cited by this paper
• Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer

  2017cited by this paper
• Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.

  2017cited by this paper
• ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients

  2017cited by this paper
• Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas.

  2017cited by this paper
• Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer

  2017cited by this paper
• Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review

  2017cited by this paper
• Liquid biopsy genotyping in lung cancer: ready for clinical utility?

  2017cited by this paper
• Milestones in pathology—from histology to molecular biology

  2017cited by this paper
• RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

  2017cited by this paper
• The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?

  2017cited by this paper
• Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.

  2017cited by this paper
• Liquid biopsy for early detection of lung cancer

  2017cited by this paper
• Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review.

  2017cited by this paper
• Circulating-tumor DNA as an early detection and diagnostic tool.

  2017cited by this paper
• Reducing Artifactual EGFR T790M Mutations in DNA from Formalin-Fixed Paraffin-Embedded Tissue by Use of Thymine-DNA Glycosylase.

  2017cited by this paper
• Liquid biopsies in lung cancer-time to implement research technologies in routine care?

  2017cited by this paper
• Treatment of choice for patients with EGFR mutation-positive non-small cell lung carcinoma presenting with choroidal metastases: radiotherapy or TKIs?

  2017cited by this paper
• Direct detection of early-stage cancers using circulating tumor DNA

  2017cited by this paper
• What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?

  2017cited by this paper
• The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA

  2016cited by this paper
• Pathologists and liquid biopsies: to be or not to be?

  2016cited by this paper
• Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR

  2016cited by this paper
• Concomitant EGFR mutations/ALK rearrangements: beyond a simple dual target.

  2016cited by this paper
• Detection and characterization of circulating tumor cells in lung cancer: Why and how?

  2016cited by this paper
• Pros: Can tissue biopsy be replaced by liquid biopsy?

  2016cited by this paper
• Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer

  2015cited by this paper
• Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?

  2014cited by this paper
• Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells.

  2014cited by this paper
• Gefitinib Treatment in EGFR Mutated Caucasian NSCLC

  2014cited by this paper
• Management of choroidal metastases.

  2014cited by this paper
• Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement.

  2014cited by this paper
• Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: promises, drawbacks and pitfalls.

  2014cited by this paper
• ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma.

  2012cited by this paper
• Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

  2012cited by this paper
• Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches

  2012cited by this paper
• Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase

  2012cited by this paper
• Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non‐small‐cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method

  2011cited by this paper
• Preoperative Circulating Tumor Cell Detection Using the Isolation by Size of Epithelial Tumor Cell Method for Patients with Lung Cancer Is a New Prognostic Biomarker

  2010cited by this paper
• Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas

  2006cited by this paper

• Blood-Based Cell-Free DNA in Ophthalmic Oncology

  2025cites this paper
• Choroidal metastasis as the first sign of small cell lung cancer: A case report

  2025cites this paper
• Liquid Biopsy and Ocular Tumors: A Review

  2024cites this paper
• Implementation of the clinical practice of liquid biopsies for thoracic oncology the experience of the RespirERA university hospital institute (Nice, France)

  2023cites this paper
• Nano-magnetic aptamer sensor incorporating AND logic recognition-launched hybridization chain reaction for organ origin identification of circulating tumor cells

  2023cites this paper
• Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients

  2021cites this paper
• Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice

  2021cites this paper
• Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report

  2021cites this paper
• Liquid Biopsy for Solid Ophthalmic Malignancies: An Updated Review and Perspectives

  2020cites this paper
• Immunhistochemische und molekularpathologische Diagnostik von Lungenkarzinomen

  2020cites this paper
• Immunhistochemische und molekularpathologische Diagnostik von Lungenkarzinomen

  2020cites this paper
• Molekulare Tumordiagnostik (Hochdurchsatzverfahren unter Einbeziehung der sogenannten „liquid biopsy“)

  2020influential citation
• Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France).

  2019cites this paper
• Liquid Biopsy and Genomic Assessment for Lung Cancer

  2019cites this paper
• The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients.

  2019cites this paper
• The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer

  2019cites this paper
• New concepts in the diagnosis and management of choroidal metastases

  2019cites this paper
• Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology

  2017cites this paper